{
  "meta": {
    "title": "Ntep_Rntcp",
    "url": "https://brainandscalpel.vercel.app/ntep-rntcp-54115434.html",
    "scrapedAt": "2025-11-29T18:35:05.925Z"
  },
  "questions": [
    {
      "id": 2340,
      "choices": [
        {
          "id": 9348,
          "text": "<p><span style=\"font-size:12pt;\">30000</span></p>"
        },
        {
          "id": 9349,
          "text": "<p><span style=\"font-size:12pt;\">100000</span></p>"
        },
        {
          "id": 9350,
          "text": "<p><span style=\"font-size:12pt;\">200000</span></p>"
        },
        {
          "id": 9351,
          "text": "<p><span style=\"font-size:12pt;\">500000</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In the plains region of a country working under the National Tuberculosis Elimination Program (NTEP), health administrators are tasked with ensuring adequate laboratory supervision for TB diagnostics. They are currently planning the deployment of Senior TB Laboratory Supervisors (STLS) to various districts. What is the maximum population coverage assigned to one Senior TB Laboratory Supervisor (STLS) in the plains for effective oversight under the National Tuberculosis Elimination Program (NTEP)?</span></p>",
      "unique_key": "Q4361437",
      "question_audio": null,
      "question_video": null,
      "map_id": 34277,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D. 500000</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The <strong>RNTCP</strong> designated ‘<strong>Microscopy Centre’</strong> is established for <strong>approx. 100,000 populations</strong>&nbsp;(50,000 in hilly and mountainous areas)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Senior TB Laboratory Supervisor</strong> (STLS) is one for every <strong>5 microscopy centres</strong> -&nbsp;1 STLS per 5 lac population (2.5 lac in hilly and mountainous areas)</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">STLS rechecks <strong>all +ve slides and 10% of all –ve slides</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>1 STLS</strong> - on <strong>5 Microscopic centre</strong> (MC) {1 MC&nbsp;for approx. 100,000 population plains /50,000 in hilly and mountainous areas}</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 478)</strong></span></p>",
      "correct_choice_id": 9351,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2005,
      "choices": [
        {
          "id": 8013,
          "text": "<p><span style=\"font-size:12pt;\">1960</span></p>"
        },
        {
          "id": 8014,
          "text": "<p><span style=\"font-size:12pt;\">1961</span></p>"
        },
        {
          "id": 8015,
          "text": "<p><span style=\"font-size:12pt;\">1962</span></p>"
        },
        {
          "id": 8016,
          "text": "<p><span style=\"font-size:12pt;\">1963</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">When was the Iodine deficiency disorders programme launched?</span></p>",
      "unique_key": "Q3848526",
      "question_audio": null,
      "question_video": null,
      "map_id": 34285,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C. 1962</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Goitre Control Programme</strong> (NGCP) launched in <strong>1962</strong> (100% centrally sponsored).&nbsp;</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Iodine Deficiency Disorders Control Programme</strong> (NIDDCP) was launched in <strong>1992.</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Global Iodine Deficiency Disorders</strong> (IDD) Day: <strong>21st October</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>National Goitre Control Programme</strong> (NGCP) launched - <strong>1962</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Park 26<sup>th</sup> edition (page 494)</strong></span></p>",
      "correct_choice_id": 8015,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2345,
      "choices": [
        {
          "id": 9368,
          "text": "<p><span style=\"font-size:12pt;\">99 DOTS</span></p>"
        },
        {
          "id": 9369,
          "text": "<p><span style=\"font-size:12pt;\">DOTS plus</span></p>"
        },
        {
          "id": 9370,
          "text": "<p><span style=\"font-size:12pt;\">Medication Event Reminder Monitor (MERM)</span></p>"
        },
        {
          "id": 9371,
          "text": "<p><span style=\"font-size:12pt;\">Nikshay Yojana</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">In a resource-limited setting, healthcare workers are discussing innovative methods to ensure adherence to long-term treatment regimens for diseases like tuberculosis (TB). They are interested in a cost-effective, scalable solution that utilizes widely available technology to monitor patient compliance. Which of the following is a low-cost, mobile phone-based technology that allows for real-time remote monitoring of patients’ daily treatment intake?</span></p>",
      "unique_key": "Q9087170",
      "question_audio": null,
      "question_video": null,
      "map_id": 34278,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A. 99 DOTS</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>99DOTS</strong> (Directly Observed Treatment, Short course) is a <strong>low-cost</strong>, <strong>mobile phone-based technology</strong> that <strong>enables real-time remote monitoring</strong> of <strong>daily intake of treatment</strong>, <strong>first</strong> introduced by the <strong>Revised National Tuberculosis Programme</strong> under the <strong>national programme in 2015</strong> in <strong>high-burden antiretroviral therapy</strong> (ART) <strong>centers</strong>.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>DOTS-99: ICT-based Adherence Support</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">To <strong>ensure adherence</strong> to TB treatment, the innovative approach involves embedding hidden phone numbers in the anti-TB blister pack's custom envelope.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">This <strong>number</strong> only becomes <strong>visible when a dose is dispensed</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>After taking</strong> their <strong>daily medication</strong>, patients make a <strong>free call to this hidden number</strong>, thereby <strong>providing high confidence</strong> that the <strong>dose has been taken</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">This system <strong>allows for real-time monitoring of drug intake</strong> and ensures <strong>greater compliance</strong>. This is a <strong>low-cost approach for monitoring</strong> and <strong>improving TB medication adherence</strong>.&nbsp;</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"color:#000000;font-size:14px;\"><img src=\"https://lh7-us.googleusercontent.com/ay1WKXU6ti_MS3bVBiddv5ZwZLEfe2nDpThUFOfeGNsVRp9-HtbXduAv8T7_Jw5T4Xo_VDB5KdTpODBm7yZL8I-DFhIdZoJ08XUN_v85MJPR-dOhG3K6lHoYIv8lUSN7OMBw92EC2ZzqWTQYMLN5dNY\" width=\"405\" height=\"269\"></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B.&nbsp;DOTS plus - refers to the treatment of MDR-TB (Category IV):&nbsp;MDR/XDR treatment</strong> is started at the <strong>DOTS-plus sites</strong> where the <strong>patient is admitted for treatment for 2/3 weeks</strong>; After adjusting the medication the patient is sent back to continue his/her treatment at his respective chest clinic/DOTS provider</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C.&nbsp;Medication Event Reminder Monitor (MERM)</strong>: Is&nbsp;an <strong>electronic pill box</strong> specially <strong>designed to monitor Multidrug-resistant TB</strong> (MDR-TB) <strong>treatment</strong>. Medications are dispensed in blister packs and each drug is placed in a different partitioned compartment within the pillbox<strong>.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:14px;\"><img src=\"https://www.ntep.in/sites/default/files/h5p/content/1427/images/file-64358b1d59ddc.jpg\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.&nbsp;Nikshay Yojana -&nbsp;Nikshay Poshan Yojana -&nbsp;</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>Financial incentive of Rs.500/-</strong> per month for <strong>each notified TB patient</strong> for <strong>duration</strong> for which the <strong>patient is on anti-TB treatment</strong>&nbsp;</span></li><li><span style=\"font-size:12pt;\">All TB patients notified on or after 1st April 2018 including&nbsp;all existing TB patients under treatment are eligible&nbsp;to receive incentives</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>DOTS 99</strong> - <strong>Low-cost</strong>, <strong>mobile phone-based technology</strong> that enables <strong>real-time remote monitoring</strong> of <strong>daily intake of treatment</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>NIKSHAY</strong>: <strong>ICT-based Surveillance Support</strong></span><br><span style=\"font-size:12pt;\">ICT enabled state-of-art surveillance system (Online monitoring software) to get notification of TB cases at diagnosis from both public and private sector including drug resistant TB patients</span></li><li><span style=\"font-size:12pt;\">Continuous monitoring and treatment adherence for all TB patients registered</span></li><li><span style=\"font-size:12pt;\">Enable tracking of all notified TB patients across TB care cycle, geographies, transfers and referrals.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong><u>Ref</u>: https://www.99dots.org/</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p>",
      "correct_choice_id": 9368,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2333,
      "choices": [
        {
          "id": 9320,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People in urban slums</span></span></p>"
        },
        {
          "id": 9321,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People in poorly ventilated or dusty conditions</span></span></p>"
        },
        {
          "id": 9322,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People who live in homes for elderly</span></span></p>"
        },
        {
          "id": 9323,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Work in hospital or health care professionals</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is assigned to a public health center focusing on Tuberculosis (TB) control. Part of the task is to identify key populations who are at increased risk for TB due to their living or working conditions, as these groups require targeted interventions and screening protocols. Which of the following populations is NOT typically considered at increased risk for exposure to Tuberculosis due to their living or work environments?</span></span></p>",
      "unique_key": "Q9526423",
      "question_audio": null,
      "question_video": null,
      "map_id": 34290,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. People who live in homes for elderly</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">While <strong>elderly individuals</strong> may have an <strong>increased risk for TB</strong> due to factors like <strong>weakened immune systems</strong>, <strong>living in homes</strong> for the <strong>elderly per se</strong> is <strong>not</strong> typically considered an <strong>increased risk environment</strong> for <strong>TB exposure</strong>, in comparison to the other 3 options, which are the absolute risk factor.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Correct:</strong> <strong>People living in urban slums</strong> are at a <strong>higher risk for TB exposure</strong> due to factors such as <strong>overcrowding</strong>, <strong>poor ventilation</strong>, and limited access to healthcare services.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct</strong>: <strong>Working or living in poorly ventilated</strong> or dusty conditions can <strong>increase</strong> the risk of <strong>TB exposure.</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Correct:</strong> <strong>Healthcare professionals</strong> and those working in <strong>hospitals</strong> are at an <strong>increased risk for TB exposure</strong>. They are often in close contact with patients who may have TB, especially in settings without adequate infection control measures.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">People who have <strong>Increased exposure to TB</strong> due to <strong>where they live or work:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in urban slums</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in poorly ventilated or dusty conditions</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are contacts of TB patients, including children</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">work in environments that are overcrowded</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">work in hospitals or are health care professionals</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>People</strong> who have <strong>limited access to quality TB services</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are from tribal populations or indigenous groups</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are homeless</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in hard-to-reach areas</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">live in homes for the elderly</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">have mental or physical disabilities</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">face legal barriers to access care</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">are lesbian, gay, bisxeual or transgender.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 235)</strong></span></span></p>",
      "correct_choice_id": 9322,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2292,
      "choices": [
        {
          "id": 9157,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Scanty</span></span></p>"
        },
        {
          "id": 9158,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1+</span></span></p>"
        },
        {
          "id": 9159,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2+</span></span></p>"
        },
        {
          "id": 9160,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3+</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is reviewing a sputum smear microscopy report for a patient suspected of having pulmonary tuberculosis. The report indicates the presence of acid-fast bacilli (AFB) on Ziehl-Neelsen staining. The resident must classify the smear result according to the NTEP guidelines for reporting smear microscopy results.&nbsp;The presence of 1 to 10 acid-fast bacilli (AFB) per oil immersion field on a sputum smear is classified as?</span></span></p>",
      "unique_key": "Q1897165",
      "question_audio": null,
      "question_video": null,
      "map_id": 34284,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;C. 2+</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Zeihl Neelsen</strong> (ZN) <strong>Staining</strong>&nbsp;(AFB Staining)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Sputum smear</strong> of a <strong>suspected TB patient</strong> is used for the <strong>diagnosis</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Acid Fast Bacilli</strong> (AFB) <strong>of TB</strong>: <strong>&lsquo;Rod shaped&rsquo;</strong> with <strong>&lsquo;beaded appearance&rsquo;</strong> (Beads: Mycolic Acid)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>&gt;10,000 bacilli per mL sputum</strong> must be <strong>present</strong> for a <strong>positive result</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Results of ZN staining</strong>: Minimum 100 fields examined</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162032.png\" style=\"height:215px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Grading criteria</strong> under <strong>ZN staining</strong> -&nbsp; <strong>1-10 bacilli per oil immersion field</strong> - <strong>2+ grade</strong>&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>ZN staining Procedure</strong> - </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Fix smear on slide</strong>: Pass slide 3 times over flame (smear upside)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Carbol Fuschin cover</strong>: Steam gently for 5 minutes over direct flame</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Washing</strong>: with de-ionised water</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Decolourisation</strong>: 25% sulphuric acid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Washing</strong>: With water</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Counter-staining</strong>: 1 minute with Loeffler&rsquo;s methylene blue</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Washing</strong>: With de-ionised water</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dry the slide</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://upload.wikimedia.org/wikipedia/commons/thumb/7/71/Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_02.jpg/1280px-Mycobacterium_tuberculosis_Ziehl-Neelsen_stain_02.jpg\" style=\"height:258px; width:400px\" /></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 212)</strong></span></span></p>",
      "correct_choice_id": 9159,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2293,
      "choices": [
        {
          "id": 9161,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1000 droplet nuclei</span></span></p>"
        },
        {
          "id": 9162,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2000 droplet nuclei</span></span></p>"
        },
        {
          "id": 9163,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3000 droplet nuclei</span></span></p>"
        },
        {
          "id": 9164,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4000 droplet nuclei</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a seminar on tuberculosis control, a question is posed to the medical residents about the transmission dynamics of Mycobacterium tuberculosis. It is emphasized that understanding the mechanisms of transmission is crucial for implementing effective infection control strategies.&nbsp;It is estimated that a single cough can generate how many droplet nuclei?</span></span></p>",
      "unique_key": "Q2137405",
      "question_audio": null,
      "question_video": null,
      "map_id": 34286,
      "difficulty_level": "difficult",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. 3000 droplet nuclei</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>cough</strong> is estimated to <strong>generate 3000 droplet nuclei</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Droplet nuclei</strong> are <strong>small respiratory droplets</strong> that may <strong>carry tubercle bacilli</strong> and can <strong>remain suspended</strong> in the <strong>air for several hours</strong>. These <strong>droplets</strong> are typically <strong>less than 5 micrometers in size</strong>, which allows them to <strong>stay airborne</strong> and <strong>potentially be inhaled</strong> by other <strong>individuals</strong>, leading to the <strong>spread of infection</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>TB bacteria remain alive</strong>: in <strong>sputum for 1 day</strong> and in <strong>droplet nuclei for 10 days</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>TB mode of transmission</strong> - Droplet infection, droplet nuclei. Droplet nuclei is a type of Indirect transmission.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A <strong>cough</strong> is estimated to <strong>generate 3000 droplet nuclei</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Textbook of Community Medicine, Rajvir Bhalwar (4th edition) (page 773)</strong></span></span></p>",
      "correct_choice_id": 9163,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2295,
      "choices": [
        {
          "id": 9169,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Isoniazid</span></span></p>"
        },
        {
          "id": 9170,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin</span></span></p>"
        },
        {
          "id": 9171,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pyrazinamide</span></span></p>"
        },
        {
          "id": 9172,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ethambutol</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 25-year-old woman with a newly diagnosed case of pulmonary tuberculosis is starting her antitubercular therapy (ATT). As the treating physician, you begin to educate her about the different medications she will be taking as part of her regimen. You explain that some drugs are bactericidal, killing the actively dividing bacteria, while others are bacteriostatic, inhibiting the growth and replication of the bacteria.</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following antitubercular drugs is known to be bacteriostatic?</span></span></p>",
      "unique_key": "Q2256417",
      "question_audio": null,
      "question_video": null,
      "map_id": 34287,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. D. Ethambutol</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ethambutol </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Ethambutol is <strong>bacteriostatic</strong> and is used in <strong>combination to prevent</strong> the <strong>emergence of resistance to other drugs</strong>. It is given <strong>orally</strong>. Its <strong>major side-effect is retrobulbar neuritis</strong>; this however does not occur at the usual dosage. <strong>Ethambutol</strong> has <strong>replaced para-amino salicylic acid</strong> (PAS) almost entirely among adults.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antitubercular Drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/07/screenshot-2024-08-07-162411.png\" style=\"height:363px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Important Facts of Antitubercular Drugs</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most effective</strong> anti-tubercular drug: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most bactericidal</strong> antitubercular drug: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most toxic</strong> antitubercular drug: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>rapid sputum conversion</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>orange discoloration of urine</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug first to <strong>develop resistance</strong>: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>contraindicated AIDS</strong> patients on <strong>Protease Inhibitors</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>contraindicated in HIV</strong>: <strong>Thiacetazone</strong> (Exfoliative dermatitis)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drugs <strong>contained in all phases</strong> of <strong>all categories of DOTS</strong>: <strong>Rifampicin</strong> and</span></span>&nbsp;<span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Injectable</strong> Antitubercular drug: <strong>Streptomycin</strong><br />\r\n\tAntitubercular drug <strong>contraindicated in pregnancy</strong>: <strong>Streptomycin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>contraindicated in children &lt; 6 years age</strong>: <strong>Ethambutol</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>Optic neuritis</strong> (Red-Green color blindness): <strong>Ethambutol</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing vestibular damage: Streptomycin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Only Bacteriostatic drug in Primary ATT Drugs - Ethambutol</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 215)</strong></span></span></p>",
      "correct_choice_id": 9172,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2297,
      "choices": [
        {
          "id": 9177,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Carried out by injecting 1 TU of PPD in 0.1 ml intradermally on the flexor surface of the left forearm</span></span></p>"
        },
        {
          "id": 9178,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Result of the test is read after 48-96 hours but 72 hours (3rd day) is the ideal.</span></span></p>"
        },
        {
          "id": 9179,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For HIV positive persons 2 mm induration is significant</span></span></p>"
        },
        {
          "id": 9180,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For persons with no risk factors for tuberculosis 15 mm is significant</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A medical resident is conducting a seminar on tuberculosis (TB) screening methods. One topic of discussion is the use of the tuberculin skin test (TST), which is commonly used in the identification of TB infection. The resident is aware that while the TST is a valuable tool in TB control, it has certain characteristics and limitations that must be understood for proper interpretation and application. Which of the following statements is NOT true regarding the tuberculin skin test (TST)?</span></span></p>",
      "unique_key": "Q1430804",
      "question_audio": null,
      "question_video": null,
      "map_id": 34288,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. For HIV positive persons 2 mm induration is significant</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C:</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Tuberculin Skin Test</strong> (TST) is used to <strong>detect exposure to tuberculosis</strong>. In <strong>HIV positive individuals</strong>, the <strong>immune response</strong> may be <strong>diminished</strong> due to the <strong>compromised immune system</strong>. Therefore, a <strong>smaller induration</strong> (5 mm, not 2 mm) is considered significant in <strong>HIV positive patients</strong>, as well as in <strong>recent contacts of active TB cases</strong>, persons with <strong>fibrotic changes on chest radiographs</strong> consistent with <strong>prior TB</strong>, and patients with <strong>organ transplants</strong> and other <strong>immunosuppressed patients</strong>. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation: </u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Correct: </strong>The <strong>TST</strong> is <strong>indeed administered by injecting 1 TU</strong> (Tuberculin Unit) of <strong>purified protein derivative</strong> (PPD) <strong>intradermally</strong> on the forearm. This is the standard method of administration<strong>.</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct: </strong>The results of the <strong>TST</strong> are typically <strong>read between 48-96 hours</strong> <strong>after administration</strong>, with 72 hours being the ideal time frame for reading the result.</span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Correct: </strong>In <strong>individuals</strong> with <strong>no known risk factors for tuberculosis</strong>, a <strong>larger induration</strong> (&ge;15 mm) is necessary to be considered significant. This is because the likelihood of TB exposure or latent infection is lower in this group.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin Test</strong> and <strong>Mantoux Test</strong> (Pirquet test or PPD Test) are the tool for <strong>detecting TB infection</strong></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin/PPD</strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin</strong>: <strong>Purified protein derivative</strong> (PPD) has <strong>replaced</strong> the <strong>antigen old tuberculin</strong> (OT).&nbsp;Tuberculins have also been prepared from atypical mycobacterium: PPD-Y (M. Kansasii), PPD-B (Battey mycobacterium), Scrofula (M. scrofulaceum)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Discovered by <strong>Von Pirquet</strong> (1907)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Standard PPD</strong> (PPD-S) <strong>contains</strong> -&nbsp;50,000 tuberculin units (TU) per mg [1TU= 0.00002 mg PPD]</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO advocates <strong>&rsquo;PPD-RT-23 with Tween-80&rsquo;</strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dosage</strong>: First strength (1TU), Intermediate strength (5TU), Second strength (250TU)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test conversion</strong> is defined as an <strong>increase of 10 mm </strong>or <strong>more within a 2-year period</strong>, regardless of age</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test in use</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mantoux intradermal test: More precise test of tuberculin sensitivity</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Heaf test: Quick, easy, reliable and cheap, preferred for testing large groups</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tine multiple puncture test unreliable, not recommended</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test</strong> is the <strong>&lsquo;only way of estimating</strong> the <strong>prevalence of infection</strong> in a <strong>population&rsquo;</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculin test has lost its sensitivity as an indicator of the true prevalence of infection, in countries with high coverage of BCG &ndash; True prevalence rates are exaggerated by infection with atypical mycobacteria and boosting effect of a second dose of tuberculin</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mantoux Test</strong> (Tool for detection of TB infection) (Pirquet Test)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img alt=\"Tuberculin Skin Test (Positive Mantoux Test) Result, Reading and  Interpretation - Jotscroll | Mantoux test, Tb test, Medical assistant  student\" src=\"https://i.pinimg.com/474x/cd/b4/a4/cdb4a48dd959cbea9ac399486b7b48a1.jpg\" style=\"height:249px; width:400px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin test conversion</strong>: Increase of &gt; 10 mm within 2 years period</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose</strong>: 1 TU of PPD in 0.1ml injected intradermally on forearm</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">WHO advocated preparation: PPD&ndash;RT&ndash;23 with Tween&ndash;80</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Is a test of prognostic significance</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Has limited validity due to lack of specificity</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Readings: Result read after 72 hrs (3d)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Only induration is measured:</span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Induration &gt;9 mm: Positive (Past OR current infection with TB)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Induration 6-9 mm: Doubtful (M. tuberculosis or Atypical mycobacteria)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Induration &lt;6 mm: Negative</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"margin-left:48px\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Results of tuberculin test must be interpreted carefully</strong>: The person&rsquo;s medical risk factors determine at which increment (5 mm, 10 mm, or 15 mm) of induration the result is considered positive</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>5 mm or more is positive in</strong>:&nbsp;</span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HIV-positive person</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Recent contacts of TB case</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Persons with nodular or fibrotic changes on chest X-ray consistent with old healed TB&nbsp;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patients with organ transplants</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Other immunosuppressed patients</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>10 mm or more is positive in:</strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Recent arrivals (less than 5 years) from high-prevalence countries</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Injection drug users</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Residents and employees of high-risk congregate settings (e.g., prisons, nursing homes,hospitals, homeless shelters, etc.)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mycobacteriology lab personnel</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Persons with clinical conditions that place them at high risk (diabetes, prolonged corticosteroid therapy, leukemia, end-stage renal disease, chronic malabsorption syndromes,low body weight)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children less than 4 years of age, or children and adolescents exposed to adults in high-risk categories</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>15 mm or more is positive in:</strong>&nbsp;Persons with <strong>no known risk factors for TB</strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 213)</strong></span></span></p>",
      "correct_choice_id": 9179,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2300,
      "choices": [
        {
          "id": 9189,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MDR TB with resistance to fluoroquinolones</span></span></p>"
        },
        {
          "id": 9190,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR TB</span></span></p>"
        },
        {
          "id": 9191,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mixed pattern resistant TB</span></span></p>"
        },
        {
          "id": 9192,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treatment failure of drug sensitive TB</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A pulmonologist is reviewing the eligibility criteria for the addition of Bedaquiline to the treatment regimen of patients with tuberculosis. Bedaquiline, a newer medication, is used in specific scenarios and patient populations based on the national guidelines to improve treatment outcomes while considering the risk of side effects.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following patients with tuberculosis is NOT typically eligible for Bedaquiline therapy according to standard tuberculosis management guidelines?</span></span></p>",
      "unique_key": "Q8281251",
      "question_audio": null,
      "question_video": null,
      "map_id": 34289,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;D. Treatment failure of drug sensitive TB</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong> is a <strong>newer medication</strong> that has been introduced for the <strong>treatment of multidrug-resistant tuberculosis</strong> (MDR-TB). Its use is generally recommended in cases where the <strong>TB strain is resistant to conventional first-line drugs</strong>. Therefore, a <strong>patient</strong> experiencing <strong>treatment failure with drug-sensitive TB</strong> (i.e., TB that responds to standard first-line anti-TB drugs) would <strong>not</strong> typically be a <strong>candidate for Bedaquiline therapy</strong>. This drug is <strong>reserved for more complex cases</strong> where the <strong>TB strain is resistant</strong> to <strong>standard treatment</strong>, not for cases where the standard treatment has failed due to other reasons like poor adherence or suboptimal drug levels.&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The following group of <strong>patients are eligible for BDQ therapy</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">MDR/RR TB with resistance to any/all fluoroquinolones (FQ) or to any/all second-line injectable agents (SLI) <strong>(Option A)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR-TB <strong>(Option B)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Mixed pattern resistant TB (XDR-TB + additional first line I second line resistant TB) <strong>(Option C)</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Treatment failure of MDR-TB + FQ/SLI resistance or XDR-TB</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>New Anti-Tubercular Drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Two</strong> new drugs named <strong>Bedaquiline</strong> and <strong>Delamanid</strong> with <strong>anti-TB effect</strong> were approved for <strong>treatment of multidrug resistant TB</strong> by The <strong>Central Drugs Standard Control Organization</strong> (CDSCO)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Introduction: <strong>Diarylquinoline drug</strong> which targets <strong>Mycobacterial ATP synthase</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Extended half-life: Present even 5.5 months after stoppage</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Significant use in culture-conversion time for MDR-TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patient selection criteria: Age 18 years or more with MDR-TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contraindications: Pregnancy, Cardiac arrhythmia</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Dosage&nbsp;</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Week 0&ndash;2&nbsp;- BDQ 400 mg daily + OBR (Optimized background regimen)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Week 3&ndash;24 - BDQ 200 mg thrice a week + OBR (Optimized background regimen)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Week 25 - End Continue other 2nd line drugs as per RNTCP</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Delamanid</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">DCG India allow 50 mg usage as Combination regimen for Pulmonary MDT-TB.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong> and <strong>Delamanid</strong> with <strong>anti-TB effect</strong> were approved for <strong>treatment of multidrug resistant TB</strong> by The <strong>Central Drugs Standard Control Organization</strong> (CDSCO).&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Bedaquiline</strong> is reserved for use in cases of <strong>MDR-TB and XDR-TB</strong>, where first-line treatments are either not effective or not tolerated.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 215)</strong></span></span></p>",
      "correct_choice_id": 9192,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2304,
      "choices": [
        {
          "id": 9205,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3</span></span></p>"
        },
        {
          "id": 9206,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4</span></span></p>"
        },
        {
          "id": 9207,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5</span></span></p>"
        },
        {
          "id": 9208,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">6</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In the outpatient clinic, a resident physician is tasked with prescribing anti-tuberculosis therapy for an adult patient diagnosed with pulmonary tuberculosis. The patient&rsquo;s weight is 60 kg, and as per the latest protocols, Fixed-Dose Combinations (FDCs) are to be used to simplify the regimen and improve adherence.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">How many tablets of the Fixed-Dose Combination (FDC) regimen should be given to a patient weighing between 50 to 64 kg according to the National Tuberculosis Elimination Programme (NTEP)?</span></span></p>",
      "unique_key": "Q4195707",
      "question_audio": null,
      "question_video": null,
      "map_id": 34275,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. B. 4</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment Protocol</strong>: <strong>NEW Guidelines</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patients are given <strong>fixed drug combinations</strong> (FDCs), on a <strong>Daily basis</strong> (1 November 2017 onwards PAN-India)</span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduced pill burden: 3&ndash;4 drugs in a single pill (as against 7 tablets earlier)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Lesser relapses</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Reduction in drug-resistance</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Greater compliance</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Paediatric patients</strong> are given <strong>easily-dissolvable</strong> and <strong>flavored drugs</strong> (instead of bitter tablets earlier)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Weight bands</strong>: Patients get appropriate dosages as per body weight</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>TB-HIV Coinfection</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">&lsquo;Intensified TB case finding and appropriate treatment&rsquo; through single window delivery of services from all ART centres</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">INH preventive therapy for prevention of TB among PLHIV</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Implementation of Pharmacovigilance by establishing adverse drug reaction monitoring centres at ART centres</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Patients not registered under DOTS</strong> are <strong>provided Intermittent</strong> (alternate day OR Thrice weekly) regimen.</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective: </u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment of TB</strong> under <strong>NTEP</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Treatment Regimen</strong> for <strong>Drug-Sensitive TB</strong> (DSTB) <strong>New</strong> and <strong>previously treated cases</strong>:&nbsp;<strong>2 HRZE</strong> (IP 56 doses) + <strong>4HRE</strong> (CP 112 doses)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Fixed Dose Combinations (FDCs): Products containing two or more active ingredients in fixed doses, used for a particular indication(s)</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Adults: 4-FDC (IP &ndash; HRZE) and 3-FDC (CP &ndash; HRE)</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Paediatric patients: Dispersible 3-FDC (HRZ) and Dispersible 2-FDC (HR)</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. Weight Bands Based Treatment</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Weight bands Adults - FIVE</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-114650.png\" style=\"height:276px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Weight bands Paediatrics - SIX</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/26/screenshot-2024-08-26-114710.png\" style=\"height:261px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. Long term Follow-up -&nbsp; After completion of treatment, the patients should be followed up clinically at the end of 6, 12,18 &amp; 24 months.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><strong>Reference: Park 26<sup>th</sup> edition (page 218)</strong></span></span></p>",
      "correct_choice_id": 9206,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2306,
      "choices": [
        {
          "id": 9213,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nikshay</span></span></p>"
        },
        {
          "id": 9214,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nitchay</span></span></p>"
        },
        {
          "id": 9215,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">End TB portal</span></span></p>"
        },
        {
          "id": 9216,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">TB mukt bharat</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">During a departmental meeting at a local health clinic, a discussion is held regarding the digitization of health records for better monitoring and follow-up of patients with tuberculosis (TB). A new medical officer who recently joined the clinic is learning about the various protocols and systems in place as per the National Tuberculosis Elimination Programme (NTEP).</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which portal is utilized for the entry and management of treatment details of patients with tuberculosis, as mandated by the National Tuberculosis Elimination Programme?</span></span></p>",
      "unique_key": "Q4848681",
      "question_audio": null,
      "question_video": null,
      "map_id": 34276,
      "difficulty_level": "beginner",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Nikshay</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NIKSHAY: ICT-based Surveillance Support</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Georgia,serif\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/11/09/image-20231109192341-1.png\" style=\"height:142px; width:354px\" /></span></span><br />\r\n&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>ICT enabled state-of-art surveillance system</strong> (Online monitoring software) to get <strong>notification of TB cases</strong> at diagnosis from <strong>both public</strong> and <strong>private sector</strong> including <strong>drug-resistant TB patients</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Continuous monitoring</strong> and <strong>treatment adherence</strong> for all <strong>TB patients registered</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Enable tracking of all notified TB patients</strong> across <strong>TB care cycle, geographies, transfers</strong> and <strong>referrals</strong>.</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NIKSHAY FLOW</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Nikshay Entry: Once the treatment regimen is finalized, all patients will be initiated on treatment after opening of the treatment card and entries are done in Nikshay</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patient flow in Nikshay:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay 1</strong>: Initiating the patient on appropriate treatment regimen</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay 2:</strong> Transfer / referral flow after initiation of treatment</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay 3:</strong> Nikshay Aushadhi</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NIKSHAY MITRA INITIATIVE</strong> (NMI)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>NMI</strong> is a part of <strong>Pradhan Mantri TB Mukt Bharat Abhiyaan</strong> launched by The <strong>President of India</strong> on September 9, 2022</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay Mitra</strong> is a <strong>government project</strong> that enables people to <strong>adopt tuberculosis patients</strong> and take care of their nutritional and medical requirement, with an aim to combat stigma associated with the disease</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay Mitra</strong> has a <strong>number of choices</strong> for help, including <strong>dietary, diagnostic, occupational</strong>, and <strong>supplementary nutritional supplements</strong>. In addition, they can select a support period of one to three years. They can select the state, district, building, and medical facilities. The district TB officer will make it easier to become Nikshay Mitra.</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Objectives of the Initiative</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Provide additional patient support to improve treatment outcomes of TB patients</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Augment community involvement in meeting India&rsquo;s commitment to end TB by 2025</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Leverage Corporate Social Responsibility (CSR) activities</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Additional assistance</strong> that may be provided by the<strong> Nikshay Mitra to on-treatment TB patients</strong>: Nutritional support, Additional investigations for the diagnosed TB patients, Vocational support, Additional nutritional supplements</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Some important Pointers about NTEP -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Nikshay Poshan Yojana:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Financial incentive of Rs 500/- per month</strong> for each notified TB patient for duration for which the patient is on anti-TB treatment</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All <strong>TB patients notified on or after 1st April 2018</strong> including all existing TB patients under treatment are eligible to receive incentive</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All TB patients who have been diagnosed and registered under NTEP will be referred for screening for Diabetes</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Two new drugs named Bedaquiline and Delamanid with anti-TB effect were approved for treatment of multidrug resistant TB by The Central Drugs Standard Control Organization (CDSCO)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 218)</strong></span></span></p>",
      "correct_choice_id": 9213,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2316,
      "choices": [
        {
          "id": 9253,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chest X ray</span></span></p>"
        },
        {
          "id": 9254,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Tuberculin skin test</span></span></p>"
        },
        {
          "id": 9255,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Gastric aspirate</span></span></p>"
        },
        {
          "id": 9256,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Serological tests</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A 5-year-old boy presents to a rural health clinic with a persistent cough, fever, and weight loss. His history reveals contact with an uncle who was recently diagnosed with pulmonary tuberculosis. The child is too young to produce a reliable sputum sample for direct acid-fast bacilli (AFB) testing, and the healthcare team must consider alternative diagnostic methods as per the National Tuberculosis Elimination Programme (NTEP) guidelines for pediatric tuberculosis cases.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Which of the following diagnostic methods is NOT recommended for detecting tuberculosis in children who cannot provide a sputum sample, according to NTEP guidelines?</span></span></p>",
      "unique_key": "Q2874780",
      "question_audio": null,
      "question_video": null,
      "map_id": 34279,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. &nbsp;D. Serological tests</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Serological tests</strong> are <strong>Banned in India</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">In situations where <strong>M. tuberculosis</strong> is <strong>not detected</strong> or a <strong>specimen is not available</strong>, <strong>chest X-ray</strong> (option A) and <strong>Tuberculin skin test</strong> (TST) (Option B) by Mantoux technique using 2 TU of PPD RT 23 should be done. <strong>Gastric aspirate</strong> (Option C) can be used.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Diagnosis of TB under NTEP/ RNTCP</span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. <strong>Microscopy:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">ZN staining-based Conventional Microscopy (First main test performed)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Light Emitting Diode-based Fluorescence Microscopy (LED FM)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. <strong>Culture</strong> (Diagnosis):</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Solid Lowenstein Jensen (LJ) Medium</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Automated Liquid Culture Systems (BACTEC MGIT 960, Bactialert, VersaTrek)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3. <strong>Culture</strong> (Drug Sensitivity Testing):</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Modified PST for MGIT 960 system (for both 1st and 2nd line drugs)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Proportional Sensitivity Testing (1%) Economic variant using LJ Medium (as back-up)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">4. <strong>Rapid Molecular Diagnostic Testing:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Line Probe Assay (MTB complex and INH/RIF resistance)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Cartridge based nucleic acid amplification test (CBNAAT&ndash;Xpert/MTB/Rif testing using GeneXpert system)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5. <strong>Other Diagnostic Tests</strong>:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Chest X-ray (Mainly for screening. If used for diagnosis its known as Clinically diagnosed TB)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Standardized Tuberculin Skin Test (Complimentary test in children)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Interferon Gamma Release Assay (IGRA&ndash;Not recommended for adults in India)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Serological tests (Banned in India).</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 224)</strong></span></span></p>",
      "correct_choice_id": 9256,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2317,
      "choices": [
        {
          "id": 9257,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 mg/kg daily for 6 months</span></span></p>"
        },
        {
          "id": 9258,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 mg/kg daily for 6 months</span></span></p>"
        },
        {
          "id": 9259,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">10 mg/kg daily for 12 months</span></span></p>"
        },
        {
          "id": 9260,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">5 mg/kg daily for 12 months</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a public health internship, a medical resident is tasked with finding the updated recent protocol for tuberculosis (TB) contact tracing and prophylaxis. One key component of the protocol involves the administration of isoniazid as a chemoprophylactic agent to prevent the development of active TB in individuals who have been in close contact with TB patients. What is the recommended dose of isoniazid for chemoprophylaxis in individuals who have been identified as close contacts of patients with tuberculosis?</span></span></p>",
      "unique_key": "Q3333427",
      "question_audio": null,
      "question_video": null,
      "map_id": 34280,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. 10 mg/kg daily for 6 months</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>dose of INH</strong> for <strong>chemoprophylaxis is 10 mg/kg</strong> (instead of 5 mg/kg) administered daily for <strong>6 months</strong>.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>INH Preventive Therapy</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">1. <strong>INH Preventive Therapy in Children</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Children &lt;6 years of age</strong> in <strong>close contact</strong> (But TB excluded)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HIV infected children who either had a known <strong>exposure to an infectious TB case</strong> or are</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Tuberculin skin test</strong> (TST) <strong>positive</strong> (&gt;=5mm induration) but have no active TB disease</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">All <strong>TST positive children</strong> who are receiving <strong>immunosuppressive therapy</strong> (e.g. Children with nephrotic syndrome, acute leukaemia, etc.)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A child born to mother who was diagnosed to have TB in pregnancy provided congenital TB has been ruled out</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">2. <strong>INH Preventive Therapy in Adults</strong> -&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adults</strong> and <strong>adolescents</strong> living with <strong>HIV</strong> <strong>unlikely</strong> to have <strong>active TB</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children living with HIV who do not have poor weight gain, fever or current cough unlikely to have active TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children living with HIV if evaluation shows no TB</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">3<strong>. Dose of IPT Used under NTEP -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Adult and Adolescent: Isoniazid 300 mg + Pyridoxine 50 mg per day &times; 6 months</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Children above 12 months: Isoniazid 10 mg/kg + Pyridoxine 25 mg per day &times; 6 months</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Important Pointers: </strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antitubercular drugs</strong> contained in <strong>all phases of all categories of DOTS</strong>: <strong>Rifampicin </strong>and <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most <strong>effective drug</strong> out of <strong>HRZES - H and R</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Antitubercular drug</strong> first to develop resistance: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Most toxic antitubercular drug: Isoniazid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Multidrug Resistant TB (MDR&ndash;TB): Resistance to Isoniazid and Rifampicin &lsquo;with or without resistance to other drugs&rsquo;</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Extensive Drug Resistant TB (XDR&ndash;TB): Resistance to rifampicin and isoniazid AND to any member of the quinolone family AND to one of the injectable second-line drugs (kanamycin, capreomycin, or amikacin)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">XDR&ndash;TB is MDR TB with further resistance to 3 &ndash; 6 classes of second line drugs (Older definition)</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose of IPT Used under NTEP</strong> -&nbsp;&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Adult and Adolescent</strong>: Isoniazid 300 mg + Pyridoxine 50 mg per day &times; 6 months</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Children above 12 months</strong>: Isoniazid 10 mg/kg + Pyridoxine 25 mg per day &times; 6 months</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 225)</strong></span></span></p>",
      "correct_choice_id": 9257,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2318,
      "choices": [
        {
          "id": 9261,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Isoniazid</span></span></p>"
        },
        {
          "id": 9262,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Rifampicin</span></span></p>"
        },
        {
          "id": 9263,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Pyrazinamide</span></span></p>"
        },
        {
          "id": 92699,
          "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Streptomycin</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 27-year-old woman who is 16 weeks pregnant presents to the clinic with a cough, night sweats, and a weight loss of 10 pounds over the last two months. A sputum sample is positive for acid-fast bacilli, and a chest X-ray is consistent with active pulmonary tuberculosis (TB). The patient is HIV negative. Her obstetrician must now collaborate with an infectious disease specialist to determine an appropriate treatment regimen that is safe for both the mother and the fetus. Which of the following anti-tuberculous medications is CONTRAINDICATED in this pregnant patient?</span></span></p>",
      "unique_key": "Q4418911",
      "question_audio": null,
      "question_video": null,
      "map_id": 34281,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. C. Streptomycin</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Before initiating treatment</strong> for <strong>tuberculosis</strong>, <strong>women of childbearing age</strong> should be asked about <strong>current or planned pregnancy</strong> and <strong>counselled appropriately</strong>. A <strong>successful treatment of TB</strong> is important for <strong>successful outcome of pregnancy</strong>. With the exception of streptomycin, the <strong>first line anti-TB drugs</strong> are <strong>safe for use in pregnancy</strong>. <strong>Streptomycin</strong> is <strong>oto-toxic</strong> to the <strong>foetus</strong> and should not be used during pregnancy.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Other 3 options (Isoniazid, Rifampicin and Pyrazinamide) are safe to use in pregnancy&nbsp;</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Important Facts of Antitubercular Drugs</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most effective</strong> anti-tubercular drug: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most bactericidal</strong> antitubercular drug: <strong>Rifampicin</strong> </span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Most toxic</strong> antitubercular drug: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>rapid sputum conversion</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing <strong>orange discoloration of urine</strong>: <strong>Rifampicin</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug <strong>first to develop resistance</strong>: <strong>Isoniazid</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated AIDS patients on Protease Inhibitors: Rifampicin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated in HIV: Thiacetazone (Exfoliative dermatitis)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drugs contained in all phases of all categories of DOTS: Rifampicin and Isoniazid</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Injectable Antitubercular drug: Streptomycin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated in children &lt; 6 years age: Ethambutol</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing Optic neuritis (Red-Green color blindness): Ethambutol</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug causing vestibular damage: Streptomycin</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Antitubercular drug contraindicated in pregnancy: Streptomycin</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 225)</strong></span></span></p>",
      "correct_choice_id": 92699,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2320,
      "choices": [
        {
          "id": 9268,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Jeryl Lynn strain is used for production of BCG vaccine</span></span></p>"
        },
        {
          "id": 9269,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">For vaccination, the usual strength is 0.1 mg in 0.1 ml volume</span></span></p>"
        },
        {
          "id": 9270,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The site of injection should be just above the insertion of the left deltoid muscle</span></span></p>"
        },
        {
          "id": 9271,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The duration of protection is from 15 to 20 years.</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a primary care clinic, a group of nursing students is being taught about the Bacille Calmette-Gu&eacute;rin (BCG) vaccine, its administration, and its role in tuberculosis prevention. The discussion covers various aspects of the vaccine, including production, dosage, administration, and duration of protection. Which of the following statements regarding the BCG vaccine is NOT accurate?</span></span></p>",
      "unique_key": "Q1110687",
      "question_audio": null,
      "question_video": null,
      "map_id": 34283,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans. A. Jeryl Lynn strain is used for production of BCG vaccine</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>Jeryl Lynn strain</strong> is used for the <strong>production of the mumps vaccine</strong>, not the BCG vaccine<strong><em>.</em></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The WHO has recommended the &quot;<strong>Danish 1331&rdquo; strain</strong> for the <strong>production of BCG vaccine</strong>. The <strong>vaccine strain</strong> is derived from <strong>Mycobacterium bovis</strong>. Since January 1967, the BCG Laboratory at Guindy, Chennai, has been using the &ldquo;Danish 1331&rdquo; strain for the production of BCG vaccine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG Vaccine -&nbsp;</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG stands for &lsquo;Bacille Calmette Guerin&rsquo;</strong> &ndash; an &lsquo;avirulent strain&rsquo; produced by 239 subcultures over a period of 13 years</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Live attenuated vaccine</strong> &ndash; Freeze dried (lyophilized) vaccine: More stable; used currently</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG is&nbsp;reconstituted with Normal Saline</strong> (NaCl) <strong>as diluent</strong>&nbsp;&ndash; Must be used within 4 hours of reconstitution</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Dose: 0.1 mL</strong> (for all ages);&nbsp;Strength: 0.1 mg in 0.1 mL</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Route: Intra-dermal</strong>&nbsp;&ndash; Tuberculin syringe (Omega microstat syringe, 1 cm steel,26-gauge needle)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Site: Skin over left deltoid muscle</strong>&nbsp;&ndash; Left deltoid muscle is chosen ONLY by convention</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Correct: </strong>The typical dosage for the BCG vaccine is 0.1 mg in a 0.1 ml volume. This is a standard concentration used in the administration of the vaccine.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Correct</strong>: The recommended site of injection for the BCG vaccine is intradermally just above the insertion of the deltoid muscle, often on the left arm. This is a common practice for ease of administration and monitoring of the site.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Correct: </strong>The duration of protection provided by the BCG vaccine is generally estimated to be between 15 to 20 years. This duration can vary based on individual immune response and other factors.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Strains of Commonly Used Vaccines</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>BCG - Danish-1331 strain</strong> (WHO recommended)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">OPV/IPV - P1, P2, P3 strains (Monovalent or Trivalent or Bivalent)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Measles vaccine</strong> - Edmonston Zagreb strain (MC);&nbsp;Schwartz strain;&nbsp;Moraten strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Mumps vaccine</strong> - Jeryll Lynn strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Rubella vaccine</strong> - RA 27/3</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Yellow Fever vaccine</strong> - 17 D strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Varicella vaccine</strong> - OKA strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Japanese Encephalitis vaccine</strong> - Nakayama strain;&nbsp;Beijing P3 strain;&nbsp;SA 14-14-2 (Used in India)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Swine Flu Vaccine</strong> (killed) - A7/California/2009</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Malaria vaccine SPf </strong>- 66 strain (Lytic Coktail);&nbsp;Pf 25 strain;&nbsp;RTS, S/AS01 (Mosquirix)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">HIV vaccines - mVA (modified Vaccinia Ankara) strain;&nbsp;rAAV (recombinant Adeno associated viral vaccine) strain;&nbsp;CTL&nbsp;(Cytotoxic T-lymphocytic) strain;&nbsp;AIDSVAX strain;&nbsp;Subunit Vaccine strain</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Typhoral vaccine - Ty 21 a</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Covaxin - Niv-2020-770</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 226)</strong></span></span></p>",
      "correct_choice_id": 9268,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 2350,
      "choices": [
        {
          "id": 9388,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">0% having catastrophic expenditure due to TB</span></span></p>"
        },
        {
          "id": 9389,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">70% increase in case finding</span></span></p>"
        },
        {
          "id": 9390,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">80% reduction in TB incidence</span></span></p>"
        },
        {
          "id": 9391,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">90% reduction in TB mortality</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">A group of public health professionals is evaluating the country&rsquo;s progress toward the targets set by the National Strategic Plan for Tuberculosis (TB) elimination. In the course of their review, they compare the set objectives against the milestones reached and strategize on how to address the gaps. Which of the following is NOT an objective within the National Strategic Plan to achieve the elimination of tuberculosis by 2025?</span></span></p>",
      "unique_key": "Q9391992",
      "question_audio": null,
      "question_video": null,
      "map_id": 34282,
      "difficulty_level": "intermediate",
      "subjects_id": [
        7
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Ans.&nbsp;B. 70% increase in case finding</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">The <strong>National Strategic Plan</strong> aims to achieve the <strong>elimination of TB by 2025</strong>. </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Under SDGs</strong>&ndash;Specific <strong>Targets for SDG Target 3.3 on Infectious Diseases</strong> -&nbsp;Targets for TB are:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. 0% patient</strong> having <strong>catastrophic expenditure</strong> due to TB</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. 80% reduction</strong> in <strong>TB incidence</strong> (i.e. reduction from 211 per lakh to 43 per lakh)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. 90% reduction</strong> in <strong>TB mortality</strong> (i.e. reduction from 32 per lakh to 3 per lakh)</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Timeline of TB Programs in India</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1962:</strong> National TB Control Program (NTP) launched [Strategy: BCG vaccination, TB treatment]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>1992-93</strong>: Revised National TB Control Program (RNTCP) launched [Strategy: DOTS]</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>01 January 2020</strong>: National TB Elimination Program (NTEP) launched</span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>SDG target</strong> (3.3) for <strong>Ending the epidemic of TB</strong> are <strong>90% reduction in TB deaths</strong>;<strong>&nbsp;80% reduction</strong> in <strong>TB incidence rate</strong> and&nbsp;<strong>Zero TB-affected families</strong> facing <strong>catastrophic costs</strong> due to TB</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>National Strategic Plan (NSP) - TB 2017-25</u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>VISION</strong>: TB-Free India with zero deaths, disease and poverty due to TB</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>GOAL:</strong> To achieve a rapid decline in burden of TB, morbidity and mortality while working towards elimination of TB in India by 2025</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">NSP sets out the strategic direction and key initiatives that the MoHFW will undertake from 2017-25 for working towards achieving the goals of eliminating TB by 2025 (Achieve SDG and End TB targets for India)</span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Approach: <strong>&lsquo;DETECT-TREAT-PREVENT-BUILD&rsquo; approach</strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Strategic Focus Areas</strong>:</span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Early diagnosis of all the TB patients</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Prompt treatment with the right drugs and regimens</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Patient financial and nutritional support</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Active case finding</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Contact tracing</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">LTBI management in high risk population</span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\">Airborne infection control</span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Ref</u></strong><strong>: Park 26<sup>th</sup> edition (page 483)</strong></span></span></p>",
      "correct_choice_id": 9389,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}